Replimune Group (REPL) FDA announcement summary

Introduction and purpose

• FDA granted accelerated approval to TUDRIQEV (RP1/vusolimogene oderparepvec-wtpg) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma after progression on PD-1 antibody-based regimens.

• The approval addresses a significant unmet need for patients with advanced melanoma who have limited treatment options and poor prognosis.

• TUDRIQEV is the first approved product validating the RPx platform and represents the first oncolytic viral combination therapy to drive immune activation in this setting.

• The announcement included details on the commercial launch strategy and operational plans.

Details of approval or decision

• Approval is based on objective response rate and duration of response from the IGNYTE study; continued approval may depend on confirmatory trial results.

• TUDRIQEV is approved in combination with nivolumab for a broad population, including all subgroups studied in the IGNYTE trial, and does not require prior BRAF therapy.

• The product is off-the-shelf, minimizing logistical complexity and treatment delays.

Impact on industry and stakeholders

• The approval provides a new treatment option for approximately 10,000 advanced melanoma patients annually in the U.S. who progress on PD-1 regimens.

• Launch strategy targets rapid adoption through early adopter accounts and extensive payer engagement, aiming for broad coverage and seamless patient access.

• Dedicated patient support program (ReplimuneConnect Plus) will assist with enrollment, insurance navigation, and financial support.

• Broad label allows use in BRAF-naïve, pretreated, and adjuvant-relapsed patients.